Press Releases

Date Title  
Toggle Summary REGENX BIOSCIENCES AND AUDENTES THERAPEUTICS ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DEVELOPMENT OF TREATMENTS FOR SERIOUS, RARE MUSCLE DISEASES USING NAV™ VECTORS
WASHINGTON & SAN FRANCISCO – July 30, 2013 – REGENX Biosciences, LLC and Audentes Therapeutics, Inc. announce that they have entered into an agreement for the development and commercialization of products to treat X-Linked Myotubular Myopathy (XLMTM) and Pompe disease
Toggle Summary AUDENTES THERAPEUTICS RAISES $30 MILLION IN SERIES A FINANCING
Funding creates premier global biotechnology company dedicated to the development of treatments for rare muscle diseases using gene therapy technology SAN FRANCISCO, CA. – July 18, 2013   – Audentes Therapeutics Inc., a recently founded biotechnology company dedicated to the development of